BCL2L1 Antibody / Bcl-X

BCL2L1 antibody detects Bcl-x, encoded by the BCL2L1 gene. Bcl-x is a member of the Bcl-2 protein family that regulates mitochondrial outer membrane permeability and controls apoptosis. This protein is best known for existing in multiple isoforms with opposing functions: the larger isoform Bcl-xL acts as an anti-apoptotic factor, while the shorter isoform Bcl-xS promotes apoptosis. BCL2L1 antibody provides researchers with an essential reagent to investigate cell survival, stress responses, and oncogenesis.

Bcl-x functions by interacting with other members of the Bcl-2 family, including Bax, Bak, and Bad. Research using BCL2L1 antibody has shown that the anti-apoptotic isoform Bcl-xL sequesters pro-apoptotic factors, preventing them from permeabilizing the mitochondrial outer membrane. This blocks cytochrome c release and subsequent caspase activation, preserving cell survival under stress conditions. Conversely, Bcl-xS antagonizes Bcl-xL and promotes apoptosis by facilitating mitochondrial permeabilization. The ratio of isoform expression therefore determines whether a cell undergoes survival or programmed cell death.

Studies with BCL2L1 antibody have revealed important roles for Bcl-x in development. Bcl-xL is required for the survival of immature neurons and erythroid progenitors during embryogenesis. Knockout models demonstrate embryonic lethality when Bcl-x is absent, highlighting its essential role in protecting developing tissues from apoptosis. These findings underscore the protein's fundamental role in balancing proliferation with programmed cell death during development.

In cancer research, Bcl-x has emerged as a major regulator of tumor cell survival and therapeutic resistance. Research using BCL2L1 antibody has shown that many cancers, including lymphomas, leukemias, lung carcinoma, and breast carcinoma, overexpress Bcl-xL. This overexpression prevents apoptosis induced by chemotherapy or radiation, leading to poor therapeutic outcomes. Small molecule inhibitors targeting Bcl-xL are under active development as strategies to re-sensitize cancer cells to apoptosis. The presence of high Bcl-xL levels is often associated with worse prognosis, demonstrating its clinical relevance.

Beyond oncology, Bcl-x is also critical in cardiovascular and neurodegenerative disease. Studies with BCL2L1 antibody have shown that Bcl-xL protects cardiomyocytes during ischemia-reperfusion injury and reduces apoptosis in neurons exposed to oxidative or excitotoxic stress. However, prolonged survival of damaged cells may contribute to pathological remodeling in the heart or persistence of dysfunctional neurons in neurodegenerative disorders. This dual role highlights the complexity of targeting Bcl-x in disease therapy.

Immune regulation also relies on Bcl-x. Research using BCL2L1 antibody has demonstrated that Bcl-x isoform balance shapes lymphocyte development, particularly during thymocyte maturation. Anti-apoptotic activity ensures survival of certain T-cell subsets, while regulation of Bcl-x levels contributes to immune tolerance and selection. These functions link Bcl-x to immune homeostasis as well as immune-mediated disease.

BCL2L1 antibody is widely used in western blotting, immunohistochemistry, and flow cytometry. Western blotting distinguishes between Bcl-xL and Bcl-xS isoforms, immunohistochemistry reveals tissue-specific expression patterns, and flow cytometry measures survival regulation within immune populations. These approaches make BCL2L1 antibody valuable for basic research, translational oncology, and clinical immunology.

By supplying validated BCL2L1 antibody reagents,